PBRM1 and neoplasm: Similarly, immunotherapy also has some response biomarkers, including Polybromo 1 mutation, PD-L1 expression, tumor microenvironment, circulating T cells, neutrophil to lymphocytes ratio, IMDC classification and so on (34, 35).